Novo Nordisk A/S (NVO) EV/Sales Ratio: 4.16x
Is Novo Nordisk A/S’s EV/Sales ratio high or low?
Novo Nordisk A/S's EV/Sales ratio of 4.16x is 62% below its 5-year average of 10.95x, near the low end of its 5-year range (3.64x–18.63x).
As of Wednesday, June 17, 2026. 19.34% below its 12-month average of 5.16x.
NVO EV/Sales Ratio Chart
NVO Average EV/Sales Ratio Chart
NVO Current vs Average EV/Sales Ratio Chart
NVO EV/Sales Ratio Metrics
EV/SALES RATIO
4.16x
EV/SALES RATIO AVG TTM
5.16x
EV/SALES RATIO AVG 3Y
10.60x
EV/SALES RATIO AVG 5Y
10.95x
EV/SALES RATIO AVG 10Y
8.99x
EV/SALES RATIO AVG 15Y
7.83x
EV/SALES RATIO AVG 20Y
6.89x
CURRENT VS TTM AVG
-19.34%
CURRENT VS 3Y AVG
-60.76%
CURRENT VS 5Y AVG
-62.02%
CURRENT VS 10Y AVG
-53.74%
CURRENT VS 15Y AVG
-46.87%
CURRENT VS 20Y AVG
-39.59%
NVO Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $193.53B | 4.16x | 5.16x | 10.60x | 10.95x |
| Amgen Inc. (AMGN)vs › | $187.59B | 6.30x | 6.19x | 6.53x | 6.38x |
| Thermo Fisher Scientific Inc. (TMO)vs › | $175.64B | 4.78x | 5.14x | 5.37x | 5.61x |
| Gilead Sciences, Inc. (GILD)vs › | $158.06B | 5.85x | 6.03x | 4.99x | 4.64x |
| Abbott Laboratories (ABT)vs › | $157.84B | 4.11x | 4.92x | 5.00x | 4.98x |
| Pfizer Inc. (PFE)vs › | $148.41B | 3.35x | 3.30x | 3.43x | 3.63x |
| Intuitive Surgical, Inc. (ISRG)vs › | $145.70B | 13.99x | 18.31x | 19.51x | 18.66x |
| Danaher Corporation (DHR)vs › | $128.06B | 5.72x | 6.61x | 7.16x | 6.99x |
| CVS Health Corporation (CVS)vs › | $127.73B | 0.48x | 0.44x | 0.43x | 0.51x |
| Stryker Corporation (SYK)vs › | $119.06B | 5.24x | 6.28x | 6.58x | 6.45x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Novo Nordisk A/S EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Novo Nordisk A/S (NVO)?
- The EV/Sales ratio for NVO stock is 4.16x.
- Is Novo Nordisk A/S's EV/Sales ratio high or low?
- Novo Nordisk A/S's EV/Sales ratio of 4.16x is 62% below its 5-year average of 10.95x, near the low end of its 5-year range (3.64x–18.63x).
- What is the TTM average EV/Sales ratio for Novo Nordisk A/S (NVO)?
- The TTM average EV/Sales ratio for NVO stock is 5.16x.
- What is the 3Y average EV/Sales ratio for Novo Nordisk A/S (NVO)?
- The 3Y average EV/Sales ratio for NVO stock is 10.60x.
- What is the 5Y average EV/Sales ratio for Novo Nordisk A/S (NVO)?
- The 5Y average EV/Sales ratio for NVO stock is 10.95x.
- What is the 10Y average EV/Sales ratio for Novo Nordisk A/S (NVO)?
- The 10Y average EV/Sales ratio for NVO stock is 8.99x.
- What is the 15Y average EV/Sales ratio for Novo Nordisk A/S (NVO)?
- The 15Y average EV/Sales ratio for NVO stock is 7.83x.
- What is the 20Y average EV/Sales ratio for Novo Nordisk A/S (NVO)?
- The 20Y average EV/Sales ratio for NVO stock is 6.89x.
Novo Nordisk A/S EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-16 | 4.16x |
| 2026-06-15 | 4.19x |
| 2026-06-12 | 4.19x |
| 2026-06-11 | 4.20x |
| 2026-06-10 | 4.10x |
| 2026-06-09 | 4.04x |
| 2026-06-08 | 3.94x |
| 2026-06-05 | 4.11x |
| 2026-06-04 | 4.18x |
| 2026-06-03 | 4.03x |
| 2026-06-02 | 4.11x |
| 2026-06-01 | 4.21x |
| 2026-05-29 | 4.34x |
| 2026-05-28 | 4.33x |
| 2026-05-27 | 4.25x |
| 2026-05-26 | 4.22x |
| 2026-05-22 | 4.28x |
| 2026-05-21 | 4.23x |
| 2026-05-20 | 4.29x |
| 2026-05-19 | 4.22x |
| 2026-05-18 | 4.22x |
| 2026-05-15 | 4.26x |
| 2026-05-14 | 4.36x |
| 2026-05-13 | 4.47x |
| 2026-05-12 | 4.46x |
| 2026-05-11 | 4.41x |
| 2026-05-08 | 4.38x |
| 2026-05-07 | 4.36x |
| 2026-05-06 | 4.35x |
| 2026-05-05 | 4.54x |
| 2026-05-04 | 4.49x |
| 2026-05-01 | 4.45x |
| 2026-04-30 | 4.29x |
| 2026-04-29 | 4.11x |
| 2026-04-28 | 4.19x |
| 2026-04-27 | 4.19x |
| 2026-04-24 | 4.19x |
| 2026-04-23 | 3.94x |
| 2026-04-22 | 4.00x |
| 2026-04-21 | 4.03x |
| 2026-04-20 | 4.13x |
| 2026-04-17 | 4.13x |
| 2026-04-16 | 4.17x |
| 2026-04-15 | 4.16x |
| 2026-04-14 | 4.02x |
| 2026-04-13 | 3.89x |
| 2026-04-10 | 3.85x |
| 2026-04-09 | 3.84x |
| 2026-04-08 | 3.86x |
| 2026-04-07 | 3.79x |
| 2026-04-06 | 3.77x |
| 2026-04-02 | 3.80x |
| 2026-04-01 | 3.75x |
| 2026-03-31 | 3.78x |
| 2026-03-30 | 3.64x |
| 2026-03-27 | 3.71x |
| 2026-03-26 | 3.75x |
| 2026-03-25 | 3.74x |
| 2026-03-24 | 3.79x |
| 2026-03-23 | 3.79x |
| 2026-03-20 | 3.76x |
| 2026-03-19 | 3.81x |
| 2026-03-18 | 3.84x |
| 2026-03-17 | 3.94x |
| 2026-03-16 | 3.95x |
| 2026-03-13 | 3.89x |
| 2026-03-12 | 3.90x |
| 2026-03-11 | 3.97x |
| 2026-03-10 | 3.96x |
| 2026-03-09 | 4.06x |
| 2026-03-06 | 3.95x |
| 2026-03-05 | 4.00x |
| 2026-03-04 | 3.94x |
| 2026-03-03 | 3.77x |
| 2026-03-02 | 3.87x |
| 2026-02-27 | 3.84x |
| 2026-02-26 | 3.86x |
| 2026-02-25 | 3.91x |
| 2026-02-24 | 3.95x |
| 2026-02-23 | 4.05x |
| 2026-02-20 | 4.78x |
| 2026-02-19 | 4.87x |
| 2026-02-18 | 4.95x |
| 2026-02-17 | 4.96x |
| 2026-02-13 | 4.98x |
| 2026-02-12 | 4.92x |
| 2026-02-11 | 4.90x |
| 2026-02-10 | 4.93x |
| 2026-02-09 | 4.96x |
| 2026-02-06 | 4.80x |
| 2026-02-05 | 4.39x |
| 2026-02-04 | 4.75x |
| 2026-02-03 | 5.05x |
| 2026-02-02 | 5.80x |
| 2026-01-30 | 5.85x |
| 2026-01-29 | 5.84x |
| 2026-01-28 | 5.93x |
| 2026-01-27 | 6.18x |
| 2026-01-26 | 6.28x |
| 2026-01-23 | 6.12x |
| 2026-01-22 | 6.11x |
| 2026-01-21 | 5.84x |
| 2026-01-20 | 5.97x |
| 2026-01-16 | 6.12x |
| 2026-01-15 | 5.63x |
| 2026-01-14 | 5.80x |
| 2026-01-13 | 5.87x |
| 2026-01-12 | 5.89x |
| 2026-01-09 | 5.79x |
| 2026-01-08 | 5.65x |
| 2026-01-07 | 5.58x |
| 2026-01-06 | 5.55x |
| 2026-01-05 | 5.44x |
| 2026-01-02 | 5.18x |
| 2025-12-31 | 5.04x |
| 2025-12-30 | 5.07x |
| 2025-12-29 | 5.10x |
| 2025-12-26 | 5.18x |
| 2025-12-24 | 5.20x |
| 2025-12-23 | 5.11x |
| 2025-12-22 | 4.78x |
| 2025-12-19 | 4.78x |
| 2025-12-18 | 4.73x |
| 2025-12-17 | 4.75x |
| 2025-12-16 | 4.86x |
| 2025-12-15 | 4.99x |
| 2025-12-12 | 4.97x |
| 2025-12-11 | 4.98x |
| 2025-12-10 | 4.87x |
| 2025-12-09 | 4.61x |
| 2025-12-08 | 4.65x |
| 2025-12-05 | 4.76x |
| 2025-12-04 | 4.77x |
| 2025-12-03 | 4.73x |
| 2025-12-02 | 4.71x |
| 2025-12-01 | 4.81x |
| 2025-11-28 | 4.90x |
| 2025-11-26 | 4.84x |
| 2025-11-25 | 4.68x |
| 2025-11-24 | 4.48x |
| 2025-11-21 | 4.73x |
| 2025-11-20 | 4.73x |
| 2025-11-19 | 4.86x |
| 2025-11-18 | 4.73x |
| 2025-11-17 | 4.81x |
| 2025-11-14 | 4.79x |
| 2025-11-13 | 4.88x |
| 2025-11-12 | 4.98x |
| 2025-11-11 | 4.88x |
| 2025-11-10 | 4.57x |
| 2025-11-07 | 4.55x |
| 2025-11-06 | 4.63x |
| 2025-11-05 | 4.81x |
| 2025-11-04 | 4.95x |
| 2025-11-03 | 5.03x |
| 2025-10-31 | 5.07x |
| 2025-10-30 | 5.12x |
| 2025-10-29 | 5.25x |
| 2025-10-28 | 5.32x |
| 2025-10-27 | 5.40x |
| 2025-10-24 | 5.41x |
| 2025-10-23 | 5.43x |
| 2025-10-22 | 5.45x |
| 2025-10-21 | 5.58x |
| 2025-10-20 | 5.67x |
| 2025-10-17 | 5.54x |
| 2025-10-16 | 5.71x |
| 2025-10-15 | 5.77x |
| 2025-10-14 | 5.76x |
| 2025-10-13 | 5.85x |
| 2025-10-10 | 5.79x |
| 2025-10-09 | 5.96x |
| 2025-10-08 | 6.05x |
| 2025-10-07 | 5.99x |
| 2025-10-06 | 6.05x |
| 2025-10-03 | 6.05x |
| 2025-10-02 | 5.97x |
| 2025-10-01 | 6.01x |
| 2025-09-30 | 5.65x |
| 2025-09-29 | 5.65x |
| 2025-09-26 | 5.66x |
| 2025-09-25 | 5.70x |
| 2025-09-24 | 5.97x |
| 2025-09-23 | 6.04x |
| 2025-09-22 | 6.16x |
| 2025-09-19 | 6.22x |
| 2025-09-18 | 6.27x |
| 2025-09-17 | 5.91x |
| 2025-09-16 | 5.82x |
| 2025-09-15 | 5.66x |
| 2025-09-12 | 5.59x |
| 2025-09-11 | 5.54x |
| 2025-09-10 | 5.54x |
| 2025-09-09 | 5.54x |
| 2025-09-08 | 5.53x |
| 2025-09-05 | 5.63x |
| 2025-09-04 | 5.71x |
| 2025-09-03 | 5.77x |
| 2025-09-02 | 5.74x |
| 2025-08-29 | 5.74x |
| 2025-08-28 | 5.71x |
| 2025-08-27 | 5.74x |
| 2025-08-26 | 5.64x |
| 2025-08-25 | 5.73x |
| 2025-08-22 | 5.79x |
| 2025-08-21 | 5.65x |
| 2025-08-20 | 5.54x |
| 2025-08-19 | 5.58x |
| 2025-08-18 | 5.48x |
| 2025-08-15 | 5.35x |
| 2025-08-14 | 5.21x |
| 2025-08-13 | 5.21x |
| 2025-08-12 | 5.10x |
| 2025-08-11 | 5.11x |
| 2025-08-08 | 5.22x |
| 2025-08-07 | 5.00x |
| 2025-08-06 | 4.67x |
| 2025-08-05 | 5.08x |
| 2025-08-04 | 5.24x |
| 2025-08-01 | 5.18x |
| 2025-07-31 | 5.06x |
| 2025-07-30 | 5.37x |
| 2025-07-29 | 5.76x |
| 2025-07-28 | 7.30x |
| 2025-07-25 | 7.57x |
| 2025-07-24 | 7.48x |
| 2025-07-23 | 7.40x |
| 2025-07-22 | 7.07x |
| 2025-07-21 | 6.88x |
| 2025-07-18 | 6.82x |
| 2025-07-17 | 6.92x |
| 2025-07-16 | 7.10x |
| 2025-07-15 | 7.12x |
| 2025-07-14 | 7.29x |
| 2025-07-11 | 7.29x |
| 2025-07-10 | 7.50x |
| 2025-07-09 | 7.37x |
| 2025-07-08 | 7.36x |
| 2025-07-07 | 7.33x |
| 2025-07-03 | 7.32x |
| 2025-07-02 | 7.38x |
| 2025-07-01 | 7.38x |
| 2025-06-30 | 7.30x |
| 2025-06-27 | 7.25x |
| 2025-06-26 | 7.17x |
| 2025-06-25 | 7.13x |
| 2025-06-24 | 7.48x |
| 2025-06-23 | 7.37x |
| 2025-06-20 | 7.79x |
| 2025-06-18 | 7.81x |
| 2025-06-17 | 7.84x |
| 2025-06-16 | 8.12x |
| 2025-06-13 | 8.40x |
| 2025-06-12 | 8.53x |
| 2025-06-11 | 8.29x |
| 2025-06-10 | 8.35x |
| 2025-06-09 | 7.96x |
| 2025-06-06 | 7.87x |
| 2025-06-05 | 7.67x |
| 2025-06-04 | 7.61x |
Showing the most recent 260 of 5,031 data points. The chart above shows the full history.
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar